As many as 31% of patients have to discontinue imatinib treatment before a complete remission is achieved due to imatinib-intolerance.[3] Furthermore, almost 60% of patients relapse within 1–2 years of imatinib discontinuation.[4] Thus, there is a need for a safer, targeted approach to treat IM-resistant CML independent of BCR-ABL point mutations that achieves a deep, sustainable cytogenetic response. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.